IMRA News and Press, IMARA Inc. From 11/30/20

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that clinical ...

BOSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of ...

IMARA Inc. (IMRA) Q3 2020 Results Earnings Conference Call November 05, 2020, 08:30 AM ET Company Participants Rahul Ballal - Chief Executive Officer Michael Gray - Chief Financial and Chief Operating Officer Conference Call Participants Joseph Schwartz - SVB Leerink Yigal Nochomovitz - Citig...

Imara (IMRA): Q3 GAAP EPS of -$0.72 in-line.Cash, cash equivalents and investments of $96.1MPress Release For further details see: Imara EPS in-line

Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 g rant ed Orphan Drug d esignation from European Commission for sickle cell disease Company to host conference...

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wi...

Imara (IMRA) has dosed the first patient in the Forte Phase 2b trial of IMR-687 for adult patients with beta-thalassemia, a rare inherited red blood cell disorder. Beta-thalassemia presents as a spectrum of disease, with patients categorized based on hemoglobin l...

BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced dosing of the first...

Gainers: AgeX Therapeutics (AGE) +260%. Alphatec (ATEC) +36%. CareDx (CDNA) +19%. Selecta Biosciences (SELB) +16%. Tiziana Life Sciences (TLSA) +13%.Losers: Cytokinetics (CYTK) -44%. Taiwan Liposome (TLC) -18%. IMARA (IMRA) -7%. GenMark Diagnostics (GNMK) -6...

Just one SPAC is scheduled for the week ahead. More SPACs may join the IPO calendar, and another wave of new filings will likely hit after Labor Day as well. Several companies are set to launch in the shortened holiday week, including software providers Unity Software (U), Snowflake (SNOW), ...